Evidence Explorer / MS-N207 / Supportive physical care / Appraised November 1, 2026
A nonrandomized controlled study combined whole-body electromyostimulation (WB-EMS) with nutritional support in people with advanced cancer. Small adjusted gains in muscle mass and body weight were reported, but selection bias, attrition and the bundled intervention limit what can be attributed to stimulation.
Evidence at a glance
- Population: 131 people with stage III–IV solid cancers; 96 intervention and 35 control.
- Regimen: 20 minutes of WB-EMS at 85 Hz twice weekly for 12 weeks, plus nutritional support in both groups.
- Completers: 58 intervention and 24 control.
- Adjusted results: skeletal muscle mass +0.53 kg (95% CI 0.08–0.98); body weight +1.02 kg (95% CI 0.05–1.98).
- Evidence label: preliminary nonrandomized evidence.
What was studied
The study reported some functional signals but no clear differences in quality of life, fatigue or blood outcomes. Body composition was measured with bioelectrical impedance, which can be influenced by hydration and illness.
Because allocation was not randomized, people able and willing to undertake WB-EMS may have differed from controls in prognosis, motivation, symptoms or support. Attrition was substantial.
What this evidence cannot establish
The trial cannot isolate the contribution of electrical stimulation from nutrition, attention or baseline differences. It does not establish improved treatment tolerance, hospitalization, survival or tumor control.
The observed mean changes are modest and may not translate into a noticeable functional benefit for an individual.
Practical safety context
Whole-body stimulation is more intensive than localized TENS. It requires trained supervision and careful intensity progression. Muscle damage, pain, falls and skin reactions are potential concerns.
Implanted electrical devices, unstable cardiac disease, thrombosis, severe neuropathy, acute infection, uncontrolled pain and certain bone-metastasis patterns may change whether it is appropriate.
Questions for the care team
- Is the program supervised by oncology rehabilitation professionals?
- What nutrition support and exercise are bundled with the device?
- Which functional measure—not just body composition—will determine whether it is helping?
Sources
- PubMed: WB-EMS controlled study — PMID 30208857
- Full text in PubMed Central — PMCID PMC6134788
- Journal article — DOI 10.1186/s12885-018-4790-y
- ClinicalTrials.gov record — NCT02293239
Source note: Full text, PubMed metadata and registry information were checked. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.
This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
